Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

U.S. Sen. Markey Places Hold on Obama’s Nominee to Lead FDA

Toni Clarke  |  January 26, 2016

(Reuters)—U.S. Sen. Edward Markey (D-Mass.) said on Monday he has placed a hold on President Barack Obama’s nominee to head the U.S. Food and Drug Administration until the agency agrees to reform its process for approving opioid painkillers. Markey wants future opioid-approval matters to be reviewed by an FDA advisory committee, and believes the committee…

Important Changes to the Meaningful Use Hardship Exception

From the College  |  January 26, 2016

As a result of recent Medicare legislation, the Center for Medicare & Medicaid Services (CMS) has launched important changes to the Meaningful Use hardship exception process, featuring a more streamlined application process. These changes will reduce the burden on eligible professionals (EPs) by condensing the application process and decreasing the amount of information that must…

With Genetic Testing Results, More May Be Better

Kathryn Doyle  |  January 26, 2016

(Reuters Health)—When people undergo genetic testing to find out whether they’re at risk for a specific disease, doctors often wonder how much information to give them. What if the genetic testing results reveal a risk for a disease the patient hadn’t been wondering about? Geneticists are “grappling with what to do with all the information…

GSK, Astra, J&J Link with Universities in New Drug Research Fund

Reuters Staff  |  January 26, 2016

LONDON (Reuters)—GlaxoSmithKline, AstraZeneca and Johnson & Johnson have joined with three leading British universities to create a new 40 million pounds ($57 million) fund backing early drug research. The Apollo Therapeutics Fund, which aims to improve the speed and potential of university research being translated into new medicines, is a further example of a trend…

2016 Deadline Imposed by Meaningful Use Program Requires Immediate Attention: Sign Up for 2 Registries by Feb. 29 or Expect Financial Penalty

Kathy Holliman  |  January 25, 2016

Meaningful Use may be changing but it is not going away—yet. Rheumatologists must sign up with two of three registries by Feb. 29 or pay significant financial penalties for not complying with this specific part of the Meaningful Use requirements. The three choices for registries include the Immunization Registry, the Syndromic Surveillance Registry and a…

Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology

Lara C. Pullen, PhD  |  January 25, 2016

In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…

Aetna’s Deal for Humana May Push Up Costs for Seniors

Diane Bartz  |  January 24, 2016

WASHINGTON (Reuters)—Aetna Inc.’s plan to buy smaller insurer Humana Inc. for $31 billion will mean seniors will pay higher Medicare Advantage premiums, according to a new report by the think tank Center for American Progress (CAP). Aetna’s proposed deal for Humana would combine Aetna’s 7% of the Medicare Advantage market with Humana’s 19%, and make…

Five Charged in U.S. with Stealing Secrets from GlaxoSmithKline

Bill Berkrot  |  January 23, 2016

REUTERS—Five people, including two former GlaxoSmithKline researchers, were charged with a scheme to steal trade secrets from the British drugmaker for potential sale in China, according to indictments announced by the U.S. Attorney’s Office in Philadelphia on Wednesday. The indictments include charges of conspiracy to steal trade secrets, conspiracy to commit wire fraud, conspiracy to…

U.S. Government Suspends Enrollment in Cigna Medicare Advantage, Drug Plans

Caroline Humer  |  January 23, 2016

(Reuters)—The U.S. government has suspended new enrollment in Cigna Corp’s Medicare Advantage health plans for seniors and standalone Medicare prescription drug plans, citing noncompliance in its appeals and grievances procedures. The government said Cigna had deficiencies in its appeals and grievances processes in both Medicare Advantage and the Medicare prescription drug program, according to a…

How to Avoid Legal Pitfalls

Richard Quinn  |  January 22, 2016

In busy rheumatology practices, mountains of paperwork for insurance companies and federal healthcare programs make it hard to keep track of what’s legal. Missing documentation is the most common way to spark an investigation. Here are a few considerations to help you avoid legal pitfalls…

  • « Previous Page
  • 1
  • …
  • 264
  • 265
  • 266
  • 267
  • 268
  • …
  • 316
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences